| MORPHOSYS AG O.N. | 87.080 / -0.09% |
| Date/Time | 10/30 / 17:09 |
| Chg. / Chg.(%) | -0.080 / -0.09% |
| Bid | 87.180 / 175 |
| Ask | 87.220 / 175 |
| Open | 85.980 |
| Previous Close | 87.160 |
| High | 87.380 |
| Low | 85.120 |
| Volume [EUR] | 737,362.020 |
| Volume [Units] | 8,488 |
| Price fixings | 95 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | TradeGate |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 86.94 |  |
87,402 |
| Cboe Europe .. | 86.98 | |
29,542 |
| London Inter.. | 86.82 | |
13,776 |
| TradeGate | 87.080 | |
8,488 |
| Cboe Europe .. | 86.94 | |
5,521 |
| Turquoise | 86.94 | |
4,986 |
| Frankfurt | 87.3400 | |
364 |
| Stuttgart | 86.840 | |
266 |
| gettex | 86.520 | |
111 |
| Hamburg | 86.54 |  |
50 |
| Vienna Globa.. | 87.16 | |
2 |
| Hannover | 85.82 | |
0 |
| Berlin | 85.80 | |
0 |
| München | 85.84 | |
0 |
| Düsseldorf | 85.74 |  |
0 |
| Lang & Schwa.. | 86.920 | |
|
| SIX Swiss Ex.. | 102.00 | ||
| Nasdaq Other.. | 98.3000 | 1,403 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Personal area
Real-timeClick on 
to activate push quotes.
to activate push quotes.